Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma

Published:2019-05-21 Issue:1 Volume:110 Page:69-76
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Ashour Reham,Ri Masaki^ORCID,Aly Sanaa Shaker,Yoshida Takashi,Tachita Takuto,Kanamori Takashi,Aoki Sho,Kinoshita Shiori,Narita Tomoko,Totani Haruhito,Masaki Ayako,Ito Asahi,Kusumoto Shigeru,Komatsu Hirokazu,Mansour Samar,Elsaied Abdelrahman A.,Iida Shinsuke

Funder

Japan Agency for Medical Research and Development

Bristol-Myers Squibb

Ministry of Higher Education, Egypt

Ministry of Education, Culture, Sports, Science and Technology

Ministry of Education, Culture, Sports, Science, and Technology

National Cancer Center Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-019-02649-3.pdf

Reference26 articles.

1. Palumbo A, Mina R. Management of older adults with multiple myeloma. Blood Rev. 2013;27:133–42.

2. Wang TF, Ahluwalia R, Fiala MA, Trinkaus KM, Cox DP, Jaenicke M, et al. The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. Leuk Lymphoma. 2014;55:337–41.

3. Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005;65:5898–906.

4. Phipps C, Chen Y, Gopalakrishnan S, Tan D. Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development. Ther Adv Hematol. 2015;6:120–7.

5. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96:284–90.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization;Frontiers in Immunology;2024-04-19

2. Killer instincts: natural killer cells as multifactorial cancer immunotherapy;Frontiers in Immunology;2023-11-28

3. Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38‐Targeted Lipid Nanoparticles;Advanced Science;2023-05-12

4. Extracellular Vesicles in Multiple Myeloma—Cracking the Code to a Better Understanding of the Disease;Cancers;2022-11-14

5. Advances in Cellular Immunotherapy in Hematologic Malignancies;Advances in Oncology;2021-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3